Pfizer Inc. (PFE)
Pfizer: This Is What Bulls Waited For
Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the massive earnings beat, with Pfizer on track to deliver at least $4.5 billion in net savings this year. Management showed extreme confidence by raising full-year EPS guidance, impressively absorbing a $0.20 charge from the strategic 3SBio deal to fuel future growth.
Pfizer experimental sickle cell drug fails phase 3 trial
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus.
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?
Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is This Ultra-High Yield Dividend Stock a Steal at a 19% Discount?
Key Points in This Article: Pfizer's (PFE) stock has fallen 19% from its 52-week high and 50% over three years due to declining COVID-19 product sales and patent cliff concerns.
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting, signaling a successful turnaround is underway. Key drugs like Vyndaqel, Paxlovid, and Lobrena drove impressive sales growth, offsetting headwinds from the Inflation Reduction Act and patent disputes. The valuation remains highly attractive, with PFE trading at a significant discount to peers and offering a robust 7.28% dividend yield.
Pfizer Q2: Dividends Speak Louder Than EPS
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other profit indicators such as dividends and buybacks. Its latest dividend declaration keeps showing pressured growth.
Pfizer CEO talks lowering drug prices, tariffs, and earnings
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings results and cost-cutting efforts.
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de Germay - Executive VP & Chief International Commercial Officer Andrew Simon Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development David M. Denton - CFO & Executive VP Francesca M.
